nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—Infarction—Ramipril—type 1 diabetes mellitus	0.0144	0.0788	CcSEcCtD
Sorafenib—PDGFRA—penis—type 1 diabetes mellitus	0.014	0.0531	CbGeAlD
Sorafenib—RET—autonomic nervous system—type 1 diabetes mellitus	0.0139	0.0525	CbGeAlD
Sorafenib—CDKL3—cardiovascular system—type 1 diabetes mellitus	0.00988	0.0374	CbGeAlD
Sorafenib—Transient ischaemic attack—Ramipril—type 1 diabetes mellitus	0.00793	0.0433	CcSEcCtD
Sorafenib—HIPK3—islet of Langerhans—type 1 diabetes mellitus	0.00555	0.021	CbGeAlD
Sorafenib—Myocardial ischaemia—Ramipril—type 1 diabetes mellitus	0.00498	0.0272	CcSEcCtD
Sorafenib—Endocrine disorder—Ramipril—type 1 diabetes mellitus	0.00483	0.0264	CcSEcCtD
Sorafenib—HIPK3—retina—type 1 diabetes mellitus	0.00475	0.018	CbGeAlD
Sorafenib—Proteinuria—Ramipril—type 1 diabetes mellitus	0.00455	0.0249	CcSEcCtD
Sorafenib—Protein urine present—Ramipril—type 1 diabetes mellitus	0.00449	0.0245	CcSEcCtD
Sorafenib—HIPK3—nephron tubule—type 1 diabetes mellitus	0.00447	0.0169	CbGeAlD
Sorafenib—Glossitis—Ramipril—type 1 diabetes mellitus	0.00434	0.0237	CcSEcCtD
Sorafenib—Drug interaction—Ramipril—type 1 diabetes mellitus	0.00431	0.0236	CcSEcCtD
Sorafenib—ZAK—cardiovascular system—type 1 diabetes mellitus	0.0041	0.0155	CbGeAlD
Sorafenib—EPHX2—retina—type 1 diabetes mellitus	0.00406	0.0154	CbGeAlD
Sorafenib—HIPK3—cardiovascular system—type 1 diabetes mellitus	0.00401	0.0152	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—type 1 diabetes mellitus	0.00399	0.0151	CbGeAlD
Sorafenib—HIPK3—kidney—type 1 diabetes mellitus	0.00393	0.0149	CbGeAlD
Sorafenib—HIPK3—pancreas—type 1 diabetes mellitus	0.0039	0.0148	CbGeAlD
Sorafenib—MKNK2—islet of Langerhans—type 1 diabetes mellitus	0.00388	0.0147	CbGeAlD
Sorafenib—EPHX2—nephron tubule—type 1 diabetes mellitus	0.00383	0.0145	CbGeAlD
Sorafenib—Neuropathy—Ramipril—type 1 diabetes mellitus	0.00376	0.0205	CcSEcCtD
Sorafenib—TIE1—cardiovascular system—type 1 diabetes mellitus	0.00375	0.0142	CbGeAlD
Sorafenib—Gynaecomastia—Ramipril—type 1 diabetes mellitus	0.00358	0.0196	CcSEcCtD
Sorafenib—RALBP1—islet of Langerhans—type 1 diabetes mellitus	0.0035	0.0133	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—type 1 diabetes mellitus	0.00345	0.013	CbGeAlD
Sorafenib—MAP3K7—retina—type 1 diabetes mellitus	0.00342	0.0129	CbGeAlD
Sorafenib—FLT3—cardiovascular system—type 1 diabetes mellitus	0.00341	0.0129	CbGeAlD
Sorafenib—FLT1—islet of Langerhans—type 1 diabetes mellitus	0.00333	0.0126	CbGeAlD
Sorafenib—MKNK2—retina—type 1 diabetes mellitus	0.00332	0.0126	CbGeAlD
Sorafenib—RAF1—islet of Langerhans—type 1 diabetes mellitus	0.00331	0.0125	CbGeAlD
Sorafenib—EPHB6—islet of Langerhans—type 1 diabetes mellitus	0.00329	0.0125	CbGeAlD
Sorafenib—MKNK1—retina—type 1 diabetes mellitus	0.00328	0.0124	CbGeAlD
Sorafenib—Hepatic failure—Ramipril—type 1 diabetes mellitus	0.00323	0.0177	CcSEcCtD
Sorafenib—Renal failure acute—Ramipril—type 1 diabetes mellitus	0.00315	0.0172	CcSEcCtD
Sorafenib—MKNK2—nephron tubule—type 1 diabetes mellitus	0.00312	0.0118	CbGeAlD
Sorafenib—FLT4—cardiovascular system—type 1 diabetes mellitus	0.0031	0.0117	CbGeAlD
Sorafenib—Dermatitis exfoliative—Ramipril—type 1 diabetes mellitus	0.00308	0.0168	CcSEcCtD
Sorafenib—UGT1A9—kidney—type 1 diabetes mellitus	0.00308	0.0116	CbGeAlD
Sorafenib—RALBP1—retina—type 1 diabetes mellitus	0.003	0.0113	CbGeAlD
Sorafenib—Cardiac failure—Ramipril—type 1 diabetes mellitus	0.00298	0.0163	CcSEcCtD
Sorafenib—Hyponatraemia—Ramipril—type 1 diabetes mellitus	0.00292	0.0159	CcSEcCtD
Sorafenib—FLT3—lymphoid tissue—type 1 diabetes mellitus	0.00287	0.0109	CbGeAlD
Sorafenib—FLT1—retina—type 1 diabetes mellitus	0.00285	0.0108	CbGeAlD
Sorafenib—RALBP1—nephron tubule—type 1 diabetes mellitus	0.00282	0.0107	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—type 1 diabetes mellitus	0.00281	0.0106	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—type 1 diabetes mellitus	0.00277	0.0105	CbGeAlD
Sorafenib—MKNK2—pancreas—type 1 diabetes mellitus	0.00273	0.0103	CbGeAlD
Sorafenib—FLT1—nephron tubule—type 1 diabetes mellitus	0.00268	0.0102	CbGeAlD
Sorafenib—RET—kidney—type 1 diabetes mellitus	0.00268	0.0101	CbGeAlD
Sorafenib—RAF1—nephron tubule—type 1 diabetes mellitus	0.00267	0.0101	CbGeAlD
Sorafenib—Abdominal pain upper—Ramipril—type 1 diabetes mellitus	0.00265	0.0145	CcSEcCtD
Sorafenib—Breast disorder—Ramipril—type 1 diabetes mellitus	0.00263	0.0143	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Ramipril—type 1 diabetes mellitus	0.00262	0.0143	CcSEcCtD
Sorafenib—FLT4—lymphoid tissue—type 1 diabetes mellitus	0.00261	0.00986	CbGeAlD
Sorafenib—Gastritis—Ramipril—type 1 diabetes mellitus	0.00257	0.014	CcSEcCtD
Sorafenib—RALBP1—cardiovascular system—type 1 diabetes mellitus	0.00253	0.00959	CbGeAlD
Sorafenib—Dysphagia—Ramipril—type 1 diabetes mellitus	0.00251	0.0137	CcSEcCtD
Sorafenib—RALBP1—kidney—type 1 diabetes mellitus	0.00248	0.00938	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—nephron tubule—type 1 diabetes mellitus	0.00247	0.00936	CbGeAlD
Sorafenib—RALBP1—pancreas—type 1 diabetes mellitus	0.00246	0.00932	CbGeAlD
Sorafenib—Pancreatitis—Ramipril—type 1 diabetes mellitus	0.00246	0.0135	CcSEcCtD
Sorafenib—PDGFRB—islet of Langerhans—type 1 diabetes mellitus	0.00244	0.00923	CbGeAlD
Sorafenib—FLT1—cardiovascular system—type 1 diabetes mellitus	0.00241	0.00912	CbGeAlD
Sorafenib—KDR—retina—type 1 diabetes mellitus	0.00241	0.00911	CbGeAlD
Sorafenib—Abdominal discomfort—Ramipril—type 1 diabetes mellitus	0.00241	0.0132	CcSEcCtD
Sorafenib—RAF1—cardiovascular system—type 1 diabetes mellitus	0.0024	0.00907	CbGeAlD
Sorafenib—FLT1—kidney—type 1 diabetes mellitus	0.00236	0.00892	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—type 1 diabetes mellitus	0.00236	0.00892	CbGeAlD
Sorafenib—Neutropenia—Ramipril—type 1 diabetes mellitus	0.00235	0.0128	CcSEcCtD
Sorafenib—RAF1—kidney—type 1 diabetes mellitus	0.00234	0.00887	CbGeAlD
Sorafenib—FLT1—pancreas—type 1 diabetes mellitus	0.00234	0.00886	CbGeAlD
Sorafenib—RAF1—pancreas—type 1 diabetes mellitus	0.00233	0.00881	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—type 1 diabetes mellitus	0.00233	0.00881	CbGeAlD
Sorafenib—Erectile dysfunction—Ramipril—type 1 diabetes mellitus	0.00231	0.0126	CcSEcCtD
Sorafenib—RET—lymphoid tissue—type 1 diabetes mellitus	0.0023	0.0087	CbGeAlD
Sorafenib—STK10—cardiovascular system—type 1 diabetes mellitus	0.00228	0.00863	CbGeAlD
Sorafenib—KDR—nephron tubule—type 1 diabetes mellitus	0.00227	0.00858	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—type 1 diabetes mellitus	0.00226	0.00855	CbGeAlD
Sorafenib—STK10—kidney—type 1 diabetes mellitus	0.00223	0.00845	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Ramipril—type 1 diabetes mellitus	0.00222	0.0121	CcSEcCtD
Sorafenib—Acute coronary syndrome—Ramipril—type 1 diabetes mellitus	0.00221	0.0121	CcSEcCtD
Sorafenib—Renal failure—Ramipril—type 1 diabetes mellitus	0.0022	0.012	CcSEcCtD
Sorafenib—Myocardial infarction—Ramipril—type 1 diabetes mellitus	0.00219	0.012	CcSEcCtD
Sorafenib—Neuropathy peripheral—Ramipril—type 1 diabetes mellitus	0.00219	0.012	CcSEcCtD
Sorafenib—Jaundice—Ramipril—type 1 diabetes mellitus	0.00218	0.0119	CcSEcCtD
Sorafenib—Stomatitis—Ramipril—type 1 diabetes mellitus	0.00218	0.0119	CcSEcCtD
Sorafenib—Hepatobiliary disease—Ramipril—type 1 diabetes mellitus	0.00212	0.0116	CcSEcCtD
Sorafenib—Epistaxis—Ramipril—type 1 diabetes mellitus	0.00211	0.0115	CcSEcCtD
Sorafenib—UGT1A1—kidney—type 1 diabetes mellitus	0.00211	0.00798	CbGeAlD
Sorafenib—KDR—cardiovascular system—type 1 diabetes mellitus	0.00204	0.00771	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—type 1 diabetes mellitus	0.00204	0.00771	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—type 1 diabetes mellitus	0.00203	0.00766	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—type 1 diabetes mellitus	0.00201	0.00762	CbGeAlD
Sorafenib—KIT—nephron tubule—type 1 diabetes mellitus	0.00201	0.00761	CbGeAlD
Sorafenib—KDR—kidney—type 1 diabetes mellitus	0.00199	0.00754	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—type 1 diabetes mellitus	0.00199	0.00752	CbGeAlD
Sorafenib—Connective tissue disorder—Ramipril—type 1 diabetes mellitus	0.00197	0.0108	CcSEcCtD
Sorafenib—STK10—lymphoid tissue—type 1 diabetes mellitus	0.00192	0.00725	CbGeAlD
Sorafenib—Erythema multiforme—Ramipril—type 1 diabetes mellitus	0.0019	0.0104	CcSEcCtD
Sorafenib—PDGFRA—lymphoid tissue—type 1 diabetes mellitus	0.0019	0.00718	CbGeAlD
Sorafenib—Tinnitus—Ramipril—type 1 diabetes mellitus	0.00187	0.0102	CcSEcCtD
Sorafenib—Flushing—Ramipril—type 1 diabetes mellitus	0.00187	0.0102	CcSEcCtD
Sorafenib—Immune system disorder—Ramipril—type 1 diabetes mellitus	0.00182	0.00992	CcSEcCtD
Sorafenib—Mediastinal disorder—Ramipril—type 1 diabetes mellitus	0.00181	0.0099	CcSEcCtD
Sorafenib—KIT—cardiovascular system—type 1 diabetes mellitus	0.00181	0.00683	CbGeAlD
Sorafenib—Arrhythmia—Ramipril—type 1 diabetes mellitus	0.0018	0.00981	CcSEcCtD
Sorafenib—Alopecia—Ramipril—type 1 diabetes mellitus	0.00178	0.0097	CcSEcCtD
Sorafenib—KIT—kidney—type 1 diabetes mellitus	0.00177	0.00668	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—type 1 diabetes mellitus	0.00176	0.00667	CbGeAlD
Sorafenib—Mental disorder—Ramipril—type 1 diabetes mellitus	0.00176	0.00962	CcSEcCtD
Sorafenib—KIT—pancreas—type 1 diabetes mellitus	0.00175	0.00664	CbGeAlD
Sorafenib—Erythema—Ramipril—type 1 diabetes mellitus	0.00175	0.00956	CcSEcCtD
Sorafenib—Malnutrition—Ramipril—type 1 diabetes mellitus	0.00175	0.00956	CcSEcCtD
Sorafenib—PDGFRB—kidney—type 1 diabetes mellitus	0.00173	0.00653	CbGeAlD
Sorafenib—PDGFRB—pancreas—type 1 diabetes mellitus	0.00171	0.00649	CbGeAlD
Sorafenib—Dysgeusia—Ramipril—type 1 diabetes mellitus	0.00171	0.00936	CcSEcCtD
Sorafenib—KDR—lymphoid tissue—type 1 diabetes mellitus	0.00171	0.00648	CbGeAlD
Sorafenib—Muscle spasms—Ramipril—type 1 diabetes mellitus	0.00168	0.00919	CcSEcCtD
Sorafenib—CSF1R—lymphoid tissue—type 1 diabetes mellitus	0.00167	0.00632	CbGeAlD
Sorafenib—Angioedema—Ramipril—type 1 diabetes mellitus	0.0016	0.00874	CcSEcCtD
Sorafenib—Syncope—Ramipril—type 1 diabetes mellitus	0.00157	0.00857	CcSEcCtD
Sorafenib—Leukopenia—Ramipril—type 1 diabetes mellitus	0.00157	0.00856	CcSEcCtD
Sorafenib—ABCC4—nephron tubule—type 1 diabetes mellitus	0.00156	0.00591	CbGeAlD
Sorafenib—Loss of consciousness—Ramipril—type 1 diabetes mellitus	0.00154	0.0084	CcSEcCtD
Sorafenib—Cough—Ramipril—type 1 diabetes mellitus	0.00153	0.00834	CcSEcCtD
Sorafenib—KIT—lymphoid tissue—type 1 diabetes mellitus	0.00152	0.00574	CbGeAlD
Sorafenib—ABCC2—nephron tubule—type 1 diabetes mellitus	0.00151	0.00573	CbGeAlD
Sorafenib—Myalgia—Ramipril—type 1 diabetes mellitus	0.00149	0.00814	CcSEcCtD
Sorafenib—Arthralgia—Ramipril—type 1 diabetes mellitus	0.00149	0.00814	CcSEcCtD
Sorafenib—PDGFRB—lymphoid tissue—type 1 diabetes mellitus	0.00148	0.00561	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 1 diabetes mellitus	0.00148	0.00808	CcSEcCtD
Sorafenib—Dry mouth—Ramipril—type 1 diabetes mellitus	0.00146	0.00796	CcSEcCtD
Sorafenib—Anaphylactic shock—Ramipril—type 1 diabetes mellitus	0.00143	0.0078	CcSEcCtD
Sorafenib—Shock—Ramipril—type 1 diabetes mellitus	0.0014	0.00768	CcSEcCtD
Sorafenib—Nervous system disorder—Ramipril—type 1 diabetes mellitus	0.0014	0.00765	CcSEcCtD
Sorafenib—Thrombocytopenia—Ramipril—type 1 diabetes mellitus	0.0014	0.00764	CcSEcCtD
Sorafenib—HTR2B—cardiovascular system—type 1 diabetes mellitus	0.0014	0.00528	CbGeAlD
Sorafenib—Skin disorder—Ramipril—type 1 diabetes mellitus	0.00139	0.00758	CcSEcCtD
Sorafenib—ABCC4—kidney—type 1 diabetes mellitus	0.00137	0.0052	CbGeAlD
Sorafenib—ABCC4—pancreas—type 1 diabetes mellitus	0.00136	0.00516	CbGeAlD
Sorafenib—Anorexia—Ramipril—type 1 diabetes mellitus	0.00136	0.00744	CcSEcCtD
Sorafenib—ABCC2—kidney—type 1 diabetes mellitus	0.00133	0.00503	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Ramipril—type 1 diabetes mellitus	0.0013	0.00711	CcSEcCtD
Sorafenib—Dyspnoea—Ramipril—type 1 diabetes mellitus	0.00127	0.00696	CcSEcCtD
Sorafenib—CYP3A5—islet of Langerhans—type 1 diabetes mellitus	0.00127	0.00481	CbGeAlD
Sorafenib—Dyspepsia—Ramipril—type 1 diabetes mellitus	0.00126	0.00687	CcSEcCtD
Sorafenib—Decreased appetite—Ramipril—type 1 diabetes mellitus	0.00124	0.00678	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Ramipril—type 1 diabetes mellitus	0.00123	0.00674	CcSEcCtD
Sorafenib—Fatigue—Ramipril—type 1 diabetes mellitus	0.00123	0.00673	CcSEcCtD
Sorafenib—Constipation—Ramipril—type 1 diabetes mellitus	0.00122	0.00667	CcSEcCtD
Sorafenib—Gastrointestinal pain—Ramipril—type 1 diabetes mellitus	0.00117	0.00638	CcSEcCtD
Sorafenib—Urticaria—Ramipril—type 1 diabetes mellitus	0.00113	0.0062	CcSEcCtD
Sorafenib—Abdominal pain—Ramipril—type 1 diabetes mellitus	0.00113	0.00617	CcSEcCtD
Sorafenib—Body temperature increased—Ramipril—type 1 diabetes mellitus	0.00113	0.00617	CcSEcCtD
Sorafenib—ABCG2—nephron tubule—type 1 diabetes mellitus	0.0011	0.00418	CbGeAlD
Sorafenib—Hypersensitivity—Ramipril—type 1 diabetes mellitus	0.00105	0.00575	CcSEcCtD
Sorafenib—CYP3A5—nephron tubule—type 1 diabetes mellitus	0.00102	0.00388	CbGeAlD
Sorafenib—Asthenia—Ramipril—type 1 diabetes mellitus	0.00102	0.0056	CcSEcCtD
Sorafenib—CYP2B6—nephron tubule—type 1 diabetes mellitus	0.00102	0.00385	CbGeAlD
Sorafenib—Pruritus—Ramipril—type 1 diabetes mellitus	0.00101	0.00552	CcSEcCtD
Sorafenib—CYP2C8—kidney—type 1 diabetes mellitus	0.000997	0.00377	CbGeAlD
Sorafenib—Diarrhoea—Ramipril—type 1 diabetes mellitus	0.000977	0.00534	CcSEcCtD
Sorafenib—Dizziness—Ramipril—type 1 diabetes mellitus	0.000944	0.00516	CcSEcCtD
Sorafenib—CYP2B6—cardiovascular system—type 1 diabetes mellitus	0.000914	0.00346	CbGeAlD
Sorafenib—Vomiting—Ramipril—type 1 diabetes mellitus	0.000908	0.00496	CcSEcCtD
Sorafenib—CYP2C9—cardiovascular system—type 1 diabetes mellitus	0.000906	0.00343	CbGeAlD
Sorafenib—CYP3A5—kidney—type 1 diabetes mellitus	0.0009	0.00341	CbGeAlD
Sorafenib—Rash—Ramipril—type 1 diabetes mellitus	0.0009	0.00492	CcSEcCtD
Sorafenib—Dermatitis—Ramipril—type 1 diabetes mellitus	0.000899	0.00491	CcSEcCtD
Sorafenib—CYP2B6—kidney—type 1 diabetes mellitus	0.000895	0.00339	CbGeAlD
Sorafenib—Headache—Ramipril—type 1 diabetes mellitus	0.000894	0.00489	CcSEcCtD
Sorafenib—CYP3A5—pancreas—type 1 diabetes mellitus	0.000894	0.00338	CbGeAlD
Sorafenib—Nausea—Ramipril—type 1 diabetes mellitus	0.000848	0.00463	CcSEcCtD
Sorafenib—CYP2B6—lymphoid tissue—type 1 diabetes mellitus	0.000768	0.00291	CbGeAlD
Sorafenib—ABCB1—islet of Langerhans—type 1 diabetes mellitus	0.000676	0.00256	CbGeAlD
Sorafenib—CYP3A4—kidney—type 1 diabetes mellitus	0.000676	0.00256	CbGeAlD
Sorafenib—CYP2D6—kidney—type 1 diabetes mellitus	0.000665	0.00252	CbGeAlD
Sorafenib—ABCB1—retina—type 1 diabetes mellitus	0.000578	0.00219	CbGeAlD
Sorafenib—ABCB1—nephron tubule—type 1 diabetes mellitus	0.000544	0.00206	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—type 1 diabetes mellitus	0.000489	0.00185	CbGeAlD
Sorafenib—ABCB1—kidney—type 1 diabetes mellitus	0.000478	0.00181	CbGeAlD
Sorafenib—ABCB1—pancreas—type 1 diabetes mellitus	0.000475	0.0018	CbGeAlD
Sorafenib—ABCB1—lymphoid tissue—type 1 diabetes mellitus	0.000411	0.00155	CbGeAlD
Sorafenib—Vismodegib—ALB—type 1 diabetes mellitus	0.000328	1	CrCbGaD
Sorafenib—MAPK11—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.58e-05	2.86e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—type 1 diabetes mellitus	1.58e-05	2.85e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF2—type 1 diabetes mellitus	1.57e-05	2.85e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—KCNJ11—type 1 diabetes mellitus	1.57e-05	2.84e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.57e-05	2.84e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL1B—type 1 diabetes mellitus	1.57e-05	2.84e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—type 1 diabetes mellitus	1.57e-05	2.84e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2—type 1 diabetes mellitus	1.57e-05	2.84e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—type 1 diabetes mellitus	1.57e-05	2.84e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ITPR3—type 1 diabetes mellitus	1.56e-05	2.83e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.56e-05	2.83e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—STAT3—type 1 diabetes mellitus	1.56e-05	2.83e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—HBA1—type 1 diabetes mellitus	1.56e-05	2.83e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GSTT1—type 1 diabetes mellitus	1.56e-05	2.83e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—type 1 diabetes mellitus	1.56e-05	2.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCR5—type 1 diabetes mellitus	1.56e-05	2.82e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EGFR—type 1 diabetes mellitus	1.55e-05	2.81e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOC3—type 1 diabetes mellitus	1.55e-05	2.81e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ITPR3—type 1 diabetes mellitus	1.55e-05	2.81e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.55e-05	2.8e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TYK2—type 1 diabetes mellitus	1.54e-05	2.8e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—STAT3—type 1 diabetes mellitus	1.54e-05	2.79e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—STAT3—type 1 diabetes mellitus	1.54e-05	2.79e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.54e-05	2.79e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.54e-05	2.79e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.54e-05	2.78e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.53e-05	2.78e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCC8—type 1 diabetes mellitus	1.53e-05	2.78e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.53e-05	2.77e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—type 1 diabetes mellitus	1.53e-05	2.76e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GSTT1—type 1 diabetes mellitus	1.53e-05	2.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—type 1 diabetes mellitus	1.52e-05	2.76e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CD86—type 1 diabetes mellitus	1.52e-05	2.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS3—type 1 diabetes mellitus	1.52e-05	2.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—type 1 diabetes mellitus	1.51e-05	2.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—INS—type 1 diabetes mellitus	1.51e-05	2.74e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—INS—type 1 diabetes mellitus	1.51e-05	2.73e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—type 1 diabetes mellitus	1.51e-05	2.73e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.5e-05	2.71e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—INS—type 1 diabetes mellitus	1.49e-05	2.69e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—INS—type 1 diabetes mellitus	1.49e-05	2.69e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—HBA1—type 1 diabetes mellitus	1.47e-05	2.67e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOC3—type 1 diabetes mellitus	1.46e-05	2.65e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—STAT3—type 1 diabetes mellitus	1.46e-05	2.65e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.46e-05	2.65e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HBA1—type 1 diabetes mellitus	1.46e-05	2.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—STAT3—type 1 diabetes mellitus	1.46e-05	2.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.46e-05	2.64e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOC3—type 1 diabetes mellitus	1.45e-05	2.63e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—type 1 diabetes mellitus	1.45e-05	2.62e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.44e-05	2.61e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—E2F1—type 1 diabetes mellitus	1.44e-05	2.6e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CD80—type 1 diabetes mellitus	1.44e-05	2.6e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTT1—type 1 diabetes mellitus	1.44e-05	2.6e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTT1—type 1 diabetes mellitus	1.42e-05	2.58e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.42e-05	2.58e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.42e-05	2.58e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—STAT3—type 1 diabetes mellitus	1.42e-05	2.58e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EGFR—type 1 diabetes mellitus	1.42e-05	2.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—type 1 diabetes mellitus	1.4e-05	2.54e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EGFR—type 1 diabetes mellitus	1.4e-05	2.54e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EGFR—type 1 diabetes mellitus	1.4e-05	2.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—type 1 diabetes mellitus	1.4e-05	2.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—type 1 diabetes mellitus	1.4e-05	2.53e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.4e-05	2.53e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.4e-05	2.53e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GCG—type 1 diabetes mellitus	1.39e-05	2.52e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CAT—type 1 diabetes mellitus	1.39e-05	2.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—type 1 diabetes mellitus	1.39e-05	2.52e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CD80—type 1 diabetes mellitus	1.37e-05	2.48e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB3—type 1 diabetes mellitus	1.37e-05	2.48e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—type 1 diabetes mellitus	1.36e-05	2.47e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—type 1 diabetes mellitus	1.36e-05	2.47e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CAT—type 1 diabetes mellitus	1.36e-05	2.47e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—INS—type 1 diabetes mellitus	1.36e-05	2.46e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.35e-05	2.44e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—STAT3—type 1 diabetes mellitus	1.35e-05	2.44e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—type 1 diabetes mellitus	1.35e-05	2.44e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.35e-05	2.44e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—STAT3—type 1 diabetes mellitus	1.35e-05	2.44e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR5—type 1 diabetes mellitus	1.34e-05	2.43e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—type 1 diabetes mellitus	1.34e-05	2.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EGFR—type 1 diabetes mellitus	1.33e-05	2.41e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EGFR—type 1 diabetes mellitus	1.33e-05	2.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.33e-05	2.4e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ITPR3—type 1 diabetes mellitus	1.33e-05	2.4e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2RA—type 1 diabetes mellitus	1.33e-05	2.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.32e-05	2.39e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.32e-05	2.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—type 1 diabetes mellitus	1.32e-05	2.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.32e-05	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—STAT3—type 1 diabetes mellitus	1.31e-05	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.31e-05	2.38e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—type 1 diabetes mellitus	1.31e-05	2.38e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.31e-05	2.38e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NOS3—type 1 diabetes mellitus	1.31e-05	2.36e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NOS3—type 1 diabetes mellitus	1.31e-05	2.36e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.3e-05	2.36e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—type 1 diabetes mellitus	1.3e-05	2.35e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—INS—type 1 diabetes mellitus	1.3e-05	2.35e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EGFR—type 1 diabetes mellitus	1.29e-05	2.34e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.28e-05	2.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CD80—type 1 diabetes mellitus	1.28e-05	2.32e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—INS—type 1 diabetes mellitus	1.26e-05	2.29e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.25e-05	2.27e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—INS—type 1 diabetes mellitus	1.25e-05	2.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HBA1—type 1 diabetes mellitus	1.25e-05	2.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EGFR—type 1 diabetes mellitus	1.25e-05	2.26e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GCG—type 1 diabetes mellitus	1.24e-05	2.25e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOC3—type 1 diabetes mellitus	1.24e-05	2.24e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EGFR—type 1 diabetes mellitus	1.23e-05	2.22e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EGFR—type 1 diabetes mellitus	1.22e-05	2.22e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTT1—type 1 diabetes mellitus	1.22e-05	2.2e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GCG—type 1 diabetes mellitus	1.22e-05	2.2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.21e-05	2.2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—STAT3—type 1 diabetes mellitus	1.21e-05	2.2e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—KCNJ11—type 1 diabetes mellitus	1.21e-05	2.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—INS—type 1 diabetes mellitus	1.21e-05	2.19e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.2e-05	2.17e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EGFR—type 1 diabetes mellitus	1.19e-05	2.16e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—type 1 diabetes mellitus	1.19e-05	2.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.19e-05	2.16e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.19e-05	2.15e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.19e-05	2.15e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—type 1 diabetes mellitus	1.18e-05	2.14e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—type 1 diabetes mellitus	1.18e-05	2.14e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAT—type 1 diabetes mellitus	1.18e-05	2.14e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—STAT3—type 1 diabetes mellitus	1.17e-05	2.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.17e-05	2.12e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EGFR—type 1 diabetes mellitus	1.17e-05	2.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EGFR—type 1 diabetes mellitus	1.17e-05	2.11e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—type 1 diabetes mellitus	1.16e-05	2.1e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.16e-05	2.1e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—type 1 diabetes mellitus	1.15e-05	2.08e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GCG—type 1 diabetes mellitus	1.15e-05	2.07e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.14e-05	2.06e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GCG—type 1 diabetes mellitus	1.14e-05	2.05e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.13e-05	2.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—type 1 diabetes mellitus	1.12e-05	2.03e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.12e-05	2.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 1 diabetes mellitus	1.12e-05	2.03e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—type 1 diabetes mellitus	1.12e-05	2.03e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—type 1 diabetes mellitus	1.11e-05	2e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CD80—type 1 diabetes mellitus	1.11e-05	2e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.1e-05	2e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—type 1 diabetes mellitus	1.1e-05	2e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—type 1 diabetes mellitus	1.1e-05	1.99e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—STAT3—type 1 diabetes mellitus	1.09e-05	1.98e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—type 1 diabetes mellitus	1.09e-05	1.98e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TYK2—type 1 diabetes mellitus	1.08e-05	1.96e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—STAT3—type 1 diabetes mellitus	1.08e-05	1.96e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—type 1 diabetes mellitus	1.08e-05	1.95e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—type 1 diabetes mellitus	1.08e-05	1.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—type 1 diabetes mellitus	1.06e-05	1.93e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—type 1 diabetes mellitus	1.06e-05	1.92e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAT—type 1 diabetes mellitus	1.05e-05	1.91e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—INS—type 1 diabetes mellitus	1.05e-05	1.89e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAT—type 1 diabetes mellitus	1.03e-05	1.86e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ITPR3—type 1 diabetes mellitus	1.02e-05	1.85e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—type 1 diabetes mellitus	1.02e-05	1.85e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—type 1 diabetes mellitus	1.02e-05	1.84e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CASP3—type 1 diabetes mellitus	1.01e-05	1.83e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF1—type 1 diabetes mellitus	1.01e-05	1.83e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—type 1 diabetes mellitus	1.01e-05	1.83e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—type 1 diabetes mellitus	1.01e-05	1.82e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—type 1 diabetes mellitus	1e-05	1.82e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—STAT3—type 1 diabetes mellitus	9.96e-06	1.8e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—STAT3—type 1 diabetes mellitus	9.96e-06	1.8e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—type 1 diabetes mellitus	9.95e-06	1.8e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—type 1 diabetes mellitus	9.94e-06	1.8e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—type 1 diabetes mellitus	9.83e-06	1.78e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GCG—type 1 diabetes mellitus	9.7e-06	1.76e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAT—type 1 diabetes mellitus	9.69e-06	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CASP3—type 1 diabetes mellitus	9.64e-06	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—type 1 diabetes mellitus	9.63e-06	1.74e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HBA1—type 1 diabetes mellitus	9.63e-06	1.74e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAT—type 1 diabetes mellitus	9.61e-06	1.74e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—type 1 diabetes mellitus	9.58e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOC3—type 1 diabetes mellitus	9.57e-06	1.73e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—STAT3—type 1 diabetes mellitus	9.46e-06	1.71e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—type 1 diabetes mellitus	9.43e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—STAT3—type 1 diabetes mellitus	9.43e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—type 1 diabetes mellitus	9.41e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTT1—type 1 diabetes mellitus	9.4e-06	1.7e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TYK2—type 1 diabetes mellitus	9.34e-06	1.69e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INS—type 1 diabetes mellitus	9.26e-06	1.68e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—type 1 diabetes mellitus	9.21e-06	1.67e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—type 1 diabetes mellitus	9.18e-06	1.66e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—type 1 diabetes mellitus	9.16e-06	1.66e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—type 1 diabetes mellitus	9.06e-06	1.64e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—type 1 diabetes mellitus	9.06e-06	1.64e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INS—type 1 diabetes mellitus	9.05e-06	1.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—type 1 diabetes mellitus	9.01e-06	1.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—type 1 diabetes mellitus	9e-06	1.63e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—type 1 diabetes mellitus	8.98e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—type 1 diabetes mellitus	8.95e-06	1.62e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—type 1 diabetes mellitus	8.59e-06	1.56e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—type 1 diabetes mellitus	8.57e-06	1.55e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—type 1 diabetes mellitus	8.5e-06	1.54e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—type 1 diabetes mellitus	8.49e-06	1.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—type 1 diabetes mellitus	8.48e-06	1.53e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—type 1 diabetes mellitus	8.3e-06	1.5e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAT—type 1 diabetes mellitus	8.21e-06	1.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—type 1 diabetes mellitus	8.18e-06	1.48e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—type 1 diabetes mellitus	8.12e-06	1.47e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—type 1 diabetes mellitus	8.1e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—type 1 diabetes mellitus	7.93e-06	1.44e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—type 1 diabetes mellitus	7.84e-06	1.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—type 1 diabetes mellitus	7.78e-06	1.41e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—type 1 diabetes mellitus	7.77e-06	1.41e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—type 1 diabetes mellitus	7.73e-06	1.4e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—type 1 diabetes mellitus	7.72e-06	1.4e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—type 1 diabetes mellitus	7.72e-06	1.4e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—type 1 diabetes mellitus	7.65e-06	1.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—type 1 diabetes mellitus	7.57e-06	1.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—type 1 diabetes mellitus	7.55e-06	1.37e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GCG—type 1 diabetes mellitus	7.49e-06	1.36e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—type 1 diabetes mellitus	7.36e-06	1.33e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—type 1 diabetes mellitus	7.18e-06	1.3e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—type 1 diabetes mellitus	7e-06	1.27e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—type 1 diabetes mellitus	6.96e-06	1.26e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—type 1 diabetes mellitus	6.96e-06	1.26e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—type 1 diabetes mellitus	6.88e-06	1.25e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—type 1 diabetes mellitus	6.87e-06	1.24e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—type 1 diabetes mellitus	6.83e-06	1.24e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—type 1 diabetes mellitus	6.6e-06	1.2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—type 1 diabetes mellitus	6.59e-06	1.19e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—type 1 diabetes mellitus	6.54e-06	1.18e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—type 1 diabetes mellitus	6.43e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—type 1 diabetes mellitus	6.41e-06	1.16e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—type 1 diabetes mellitus	6.38e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAT—type 1 diabetes mellitus	6.34e-06	1.15e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—type 1 diabetes mellitus	6.26e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—type 1 diabetes mellitus	6.13e-06	1.11e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—type 1 diabetes mellitus	5.99e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—type 1 diabetes mellitus	5.94e-06	1.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—type 1 diabetes mellitus	5.94e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—type 1 diabetes mellitus	5.9e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—type 1 diabetes mellitus	5.85e-06	1.06e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—type 1 diabetes mellitus	5.66e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—type 1 diabetes mellitus	5.64e-06	1.02e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—type 1 diabetes mellitus	5.59e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—type 1 diabetes mellitus	5.45e-06	9.87e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—type 1 diabetes mellitus	5.29e-06	9.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—type 1 diabetes mellitus	5e-06	9.05e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—type 1 diabetes mellitus	4.78e-06	8.65e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—type 1 diabetes mellitus	4.57e-06	8.27e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—type 1 diabetes mellitus	4.21e-06	7.62e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—type 1 diabetes mellitus	3.86e-06	6.98e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—type 1 diabetes mellitus	3.69e-06	6.68e-06	CbGpPWpGaD
